Metrics as of 10/17/2026, 07:28 AM (Berlin time), refresh in progress.
BioAge Labs Stock
BioAge Labs Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kristen Fortney
- Employees
- 61
- Market cap
- $182 M
- IPO
- 26/09/2024
US-based BioAge Labs Inc. (BIOA) operates in the healthcare and biotechnology sectors, focusing on the development of therapeutics for metabolic diseases. Headquartered in Emeryville, the company utilizes a technological platform to identify new therapeutic targets by analyzing molecular changes occurring during the…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
BioAge Labs stock: price history
1D
-9.5%
1W
-23.7%
1M
-37.5%
6M
-73.8%
YTD
-63.4%
1Y
-5.3%
2Y
-80.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~43% weaker price swings than usual
BioAge Labs stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
BioAge Labs Inc. is a clinical biopharmaceutical company focused on developing therapeutics for metabolic diseases. The business model leverages a technology platform and differentiated human datasets to identify molecular changes in the aging process. A central asset is the NLRP3 inhibitor BGE 102 for treating cardiovascular and ocular diseases. Additionally, APJ agonists are being developed for obesity therapy. In a collaboration with Novartis Pharma AG, the company validates novel drug targets through investigation of biological mechanisms. The company primarily focuses on research and clinical development of new medicines.
- Revenue model
- Mixed
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about BioAge Labs
Analyst assessment of BioAge Labs
PRICE TARGET LOW
US$8.00
CONSENSUS
US$23.50
MEDIAN
US$23.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
5
BUY
1
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 09/09/2026
BioAge Labs stock metrics
P/E
-2.03
P/B
0.58
EV/EBITDA
-1.18
RETURN ON EQUITY
-7.0%
NET MARGIN
-1,064.7%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.1%
FLOAT SHARES
31,666,262
AVG. DAILY VOLUME (30D)
803,648
Insider transactions (SEC)
Barton Shane
Barton Shane
Barton Shane
Barton Shane
Barton Shane
Attention
Price since yesterday: -9.5%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about BioAge Labs stock
What does BioAge Labs do?
BioAge Labs Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kristen Fortney, the company employs around 61 people.
The IPO was on 26/09/2024; the stock trades on NASDAQ under the ticker BIOA.
What do analysts say about BioAge Labs stock?
6 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$23.50, ranging from US$8.00 to US$40.00, with a median of US$23.00.
This is an external assessment, not a statement by Market Jury.
When does BioAge Labs report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -43% stronger than usual.
Does BioAge Labs pay a dividend?
No, BioAge Labs currently does not pay a dividend.
Which stocks are comparable to BioAge Labs?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioAge Labs stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioAge Labs against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.